Our Pipeline:

DARE-BV1

Curative potential for the most common vaginal infection

Bacterial vaginosis (BV) is the most common type of vaginal infection in women of reproductive age. In the U.S. alone, an estimated 21 million women aged 14-49 years have BV. Current treatment often consists of oral antibiotics, but research has shown effective drug delivery is essential to optimizing drug therapy for BV.

DARE-BV1 is a thermosetting vaginal gel formulated with clindamycin phosphate 2% designed for prolonged, localized release of the antibiotic. In an investigator-initiated proof-of-principal study, an 86% clinical cure rate after one dose of DARE-BV1 was demonstrated (n=28).

A single Phase 3 clinical trial of DARE-BV1, if successful, is expected to support US FDA marketing approval.

Read next about OVAPRENE®